Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome ...Middle East

SHANGHAI and HONG KONG, May 27, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology...

Hence then, the article about antengene announces first patient dosed in phase i ii trial of eltanexor for the treatment of myelodysplastic syndrome was published today ( Friday 28/05/2021 - 03:32 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome )

Also on site :

• Nigel Farage’s Reform UK party receives second big donation from crypto investor
• Apollo Global Management, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - APO
• Russian Ambassador to Canada: “Ottawa” supported use of force against Iran, & our relations have been in a ‘Deep Freeze’ since 2014